Valneva SE VALN has signed an advance purchase agreement with the Kingdom of Bahrain to supply one (1) million doses of its inactivated COVID-19 vaccine candidate VLA2001.
- This is the second purchase agreement Valneva has secured for VLA2001 since reporting data for its Phase 3 trial Cov-Compare.
- Valneva has initiated a rolling submission process with the Bahraini National Health Regulatory Authority.
- The Company plans to start deliveries in the Q1 of 2022.
- Last month, Valneva announced that the European Commission signed an advanced purchase agreement for up to 60 million doses of VLA20011.
- Related Link: Valneva's COVID-19 Shot Fails As Booster In Pfizer/BioNTech Vaccinated Population.
- Price Action: VALN shares are up 13.3% at $54.38 during the premarket session on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in